Status:
COMPLETED
BOTOX® in the Treatment of Crow's Feet Lines in China
Lead Sponsor:
Allergan
Conditions:
Lateral Canthal Lines
Crow's Feet Lines
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study will evaluate the safety and efficacy of BOTOX® (botulinum toxin Type A) compared with placebo in patients with moderate to severe crow's feet lines (lateral canthal lines).
Eligibility Criteria
Inclusion
- Moderate to severe Crow's Feet Lines.
Exclusion
- Current or previous treatment with botulinum toxin of any serotype for any condition within the last year
- Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis
- Facial laser or light treatment, microdermabrasion or chemical peels within 3 months
- Radio frequency laser treatments, phototherapy, blepharoplasty, brow-lift or related procedure, permanent make-up, oral retinoid therapy or treatment with non-permanent soft tissue fillers within 1 year
- Any medium-depth or deep facial peels within 5 years
- Periorbital surgery, face-lift, mid facial or periorbital treatment with permanent soft tissue fillers, synthetic implants or autologous fat transplant.
Key Trial Info
Start Date :
September 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2015
Estimated Enrollment :
417 Patients enrolled
Trial Details
Trial ID
NCT02195687
Start Date
September 1 2014
End Date
June 1 2015
Last Update
March 14 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing, China